{"id":"NCT00137969","sponsor":"Genentech, Inc.","briefTitle":"A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus","officialTitle":"Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2005-05-10","primaryCompletion":"2008-08-25","completion":"2008-08-25","firstPosted":"2005-08-30","resultsPosted":"2010-12-10","lastUpdate":"2019-08-20"},"enrollment":262,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Lupus Erythematosus, Systemic"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan","MabThera","Zytux"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Acetaminophen","otherNames":[]},{"type":"DRUG","name":"Diphenhydramine","otherNames":[]}],"arms":[{"label":"Rituximab 1000 mg + prednisone","type":"EXPERIMENTAL"},{"label":"Placebo + prednisone","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab compared with placebo when combined with a single stable background immunosuppressive medication in subjects with moderate to severe systemic lupus erythematosus (SLE). The primary efficacy endpoint of the trial will be evaluated at 52 weeks.","primaryOutcome":{"measure":"Number of Participants Who Achieved a Major Clinical Response (MCR), Partial Clinical Response (PCR), or Nonclinical Response (NCR) Defined by British Isles Lupus Assessment Group (BILAG) Scores Over The 52-week Treatment Period","timeFrame":"From baseline to 52 weeks","effectByArm":[{"arm":"Rituximab 1000 mg + Prednisone","deltaMin":21,"sd":null},{"arm":"Placebo + Prednisone","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4875"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":25},"locations":{"siteCount":65,"countries":["United States","Canada"]},"refs":{"pmids":["20039413"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":169},"commonTop":["Upper Respiratory Tract Infection","Urinary Tract Infection","Nausea","Headache","Arthralgia"]}}